Beeline Medicines

Let's get to what matters

Boston, United States · Founded 2025 · $726.3M raised

Headquarters
Boston
Founded
2025
Business Model
B2B
Total Funding
$726.3M
Last Round
$426.3M Series AJul 2026
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Beeline Medicines is a clinical-stage biotechnology company, created by Bristol Myers Squibb and Bain Capital in 2025, developing precision therapies that target the underlying drivers of autoimmune and inflammatory disease. Its lead program, afimetoran, is an oral TLR7/8 inhibitor in Phase 2 trials for systemic and cutaneous lupus with FDA Fast Track designation, alongside a pipeline including BLN-326 (an IL-2-CD25 fusion protein), lomedeucitinib (a TYK2 inhibitor), and two preclinical biologics. The company is headquartered in Boston, Massachusetts.

Summary

Beeline Medicines is a Biotech company based in Boston, United States, founded in 2025. It has raised $726.3M in total across 2 rounds, most recently a $426.3M Series A round in Jul 2026. Investors include Bain Capital, Canada Pension Plan Investment Board and Bristol Myers Squibb.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries A (Upsized)Jul 2026
$426.3M

Sign up to see all 2 events

Funding: Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Beeline Medicines on Indexed.vc
<a href="https://indexed.vc/companies/beeline-medicines"><img src="https://indexed.vc/api/badge/company/beeline-medicines" alt="Beeline Medicines on Indexed.vc" width="260" height="76" /></a>